|Over a week ago|
Sangamo call volume above normal and directionally bullish » 10:4503/2003/20/20
Bullish option flow…
Bullish option flow detected in Sangamo with 1,004 calls trading, 1.2x expected, and implied vol increasing over 37 points to 115.54%. Apr-20 6 calls and Mar-20 6 calls are the most active options, with total volume in those strikes near 750 contracts. The Put/Call Ratio is 0.07. Earnings are expected on May 6th.
|Over a month ago|
Fly Intel: Wall Street's top stories for Friday » 16:2902/2802/28/20
HPQ, XRX, DELL, MYL, REGN, TPC, APO, SGMO, FTCH, W, GKOS, BYND
Stocks slid further on…
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair » 15:4202/2802/28/20
William Blair analyst…
William Blair analyst Matt Phipps maintained a Market Perform rating on Biogen (BIIB) following the company's strategic collaboration with Sangamo (SGMO) to "develop a broad range of Sangamo's gene regulation therapies in neuromuscular and neurological diseases." The analyst said that "while the deal likely makes sense given Biogen's portfolio and comes with relatively favorable terms, it is unlikely to impact the company in the near term, given the preclinical nature of the program." Phipps believes the company needs "near-term growth drivers outside of the uncertainty of aducanumab."
Fly Intel: Wall Street's top stories at midday » 12:0202/2802/28/20
MMM, HPQ, XRX, DELL, MSFT, APT, SGMO, FTCH, W, GKOS, BYND
The market rout has…
Fly Intel: Pre-market Movers » 09:0302/2802/28/20
ALT, LAKE, ZM, SGMO, AMC, TTD, W, BIG, BYND, VMW, CHK, APT
HIGHER AMID CORONAVIRUS…
Sangamo to hold a conference call » 08:0102/2802/28/20
Conference call to…
Conference call to discuss the licensing collaboration agreement with Biogen to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, will be held on February 28 at 8 am. Webcast Link
Sangamo reports Q4 EPS 4c, consensus (33c) » 07:1102/2802/28/20
SGMO, PFE, SNY
Reports Q4 revenue…
Reports Q4 revenue $54.85M, consensus $15.54M. The increase in revenue was primarily attributable to a $25M milestone Sangamo (SGMO) achieved for the completion of the IND transfer for SB-525 to Pfizer (PFE) for hemophilia A, and a $7.5M milestone achieved for dosing the first subject in the BIVV003 sickle cell disease Phase 1/2 clinical trial partnered with Sanofi (SNY).
Fly Intel: After Hours Movers » 19:1202/2702/27/20
SCOR, FTCH, ZYXI, SWN, ICAD, NPTN, AMC, TTD, NKTR, FTAI, WDAY, LYV, OPRX, SGMO, FTSV, BHVN, GDI, BIG, GPOR, BYND, RUN, CHRS, GKOS, AAOI, VMW, EB, AAXN, MYL, IQ, SPPI, DELL, CARA, ADSK, RIGL, PSTG, BBBY
UP AFTER EARNINGS:…
UP AFTER EARNINGS: comScore (SCOR) up 20.5%... Farfetch (FTCH) up 15.7%... Zynex (ZYXI) up 11.6%... Southwestern Energy (SWN) up 10.0%... iCAD (ICAD) up 10.0%... NeoPhotonics (NPTN) up 10.0%... AMC Entertainment (AMC) up 8.1%... Trade Desk (TTD) up 6.2%... Nektar Therapeutics (NKTR) up 5.9%...Fortress Transportation (FTAI) up 4.0%... Workday (WDAY) up 2.5%... Live Nation (LYV) up 2.2%... OptimizeRX (OPRX) up 2.1%. ALSO HIGHER: Sangamo (SGMO) up 39.5% after entering gene regulation therapy partnership with Biogen... Forty Seven (FTSV) up 29.1% after Bloomberg speculation about approach from Gilead... Biohaven (BHVN) up 6.0% after getting FDA approval for acute treatment of migraine... Garden Denver (GDI) up 2.1% after entering S&P500 index... DOWN AFTER EARNINGS: Big Lots (BIG) down 28.3%... Gulfport Energy (GPOR) down 11.1%... Beyond Meat (BYND) down 10.0%... Sunrun (RUN) down 10.0%... Coherus BioSciences (CHRS) down 8.8%... Glaukos (GKOS) down 7.5%... Applied Optoelectronics (AAOI) down 6.8%... VMWare (VMW) down 6.0%... Eventbrite (EB) down 5.4%... Axon Enterprise (AAXN) down 4.2%... Mylan (MYL) down 3.6%... iQIYI (IQ) down 3.4%... Spectrum Pharma (SPPI) down 3.3%... Dell Technologies (DELL) down 3.3%... Cara Therapeutics (CARA) down 3.2%... Autodesk (ADSK) down 2.6%... Rigel Pharma (RIGL) down 2.5%... Pure Storage (PSTG) down 2.1%. ALSO LOWER: Bed Bath Beyond (BBBY) down 2.0% after announcing strategic restructuring and job cuts. Movers as of 18:30ET.
Biogen, Sangamo announce global collaboration on gene regulation therapies » 16:4402/2702/27/20
Biogen (BIIB) and Sangamo…
Biogen (BIIB) and Sangamo Therapeutics (SGMO) announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. Under the terms of the collaboration, Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, and a third undisclosed neuromuscular disease target. In addition, Biogen has exclusive rights to nominate up to nine additional undisclosed targets over a target selection period of five years. Sangamo will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the investigational new drug-enabling studies, clinical development, related regulatory interactions, and global commercialization. Sangamo will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Upon closing of this transaction, Sangamo will receive $350M comprised of $125M in a license fee payment and $225M from the sale of new Sangamo stock, or approximately 24M shares at $9.21 per share. In addition, Sangamo may receive up to $2.37B in other development, regulatory, and commercial milestone payments, including up to $925M in pre-approval milestone payments and up to $1,445M in first commercial sale and other sales-based milestone payments. Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.
Biogen, Sangamo announce global collaboration over gene regulation therapies » 16:1202/2702/27/20
Biogen Inc. (BIIB) and…
Biogen Inc. (BIIB) and Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. "As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. We aim to develop and advance these programs forward to investigational new drug applications," said Alfred Sandrock Jr., M.D., Ph.D., Executive Vice President, Research and Development at Biogen.